NEW YORK, Jan. 18, 2022 /PRNewswire/ -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq: PTPI), a leading provider of therapeutics for men's health, has initiated two self-selection ...

Choosing the right erectile dysfunction medication can feel overwhelming for many people who are trying to understand how ED drugs differ in effectiveness, timing, side effects, and cost. With several ...

Top-line Results Show Significant Improvement in Erectile Function in Difficult-to-Treat Patients MOUNTAIN VIEW, Calif., May 25, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced ...

MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- VIVUS, Inc. (VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of ...

CHICAGO -- The newest drug for erectile dysfunction (ED) may work in as little as 15 minutes after dosing, researchers said here. A significantly larger proportion of patients had successful sexual ...

VIVUS Announces Study Results Showing STENDRA (Avanafil) is Effective for Sexual Activity Within 15 Minutes in Men With Erectile Dysfunction (ED) Data From Successful Placebo-Controlled Study to be ...

NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug ...

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has filed a New Drug Submission (“NDS”) for Avanafil with Health Canada.

SINGAPORE--(BUSINESS WIRE)--Mitsubishi Tanabe Pharma Corporation (TSE: 4508), and Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini AP”) have entered into a licensing agreement to ...

MOUNTAIN VIEW, Calif., Aug. 1, 2013 -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it has entered into a Commercial Supply Agreement with Sanofi Chimie ("Sanofi"), a wholly owned subsidiary of ...